Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 42 patients with primary open-angle glaucoma or ocular hypertension already on timolol 0.5 percent, with pressure 19 to 24 mmHg
- Dose used in the study
- PEA 300 mg tablets twice daily or vehicle placebo, added to timolol
- Duration
- 2 months, 2-month washout, then 1 month on the other treatment (crossover)
- What was measured
- Intraocular pressure, best-corrected visual acuity and visual field
What the authors reported
On PEA, pressure fell by 3.2 mmHg at 1 month and 3.5 mmHg (15.9 percent) at 2 months from a baseline of 21.6. On placebo it fell by 0.4 and 0.3 mmHg (p < 0.001 versus PEA). No changes in vital signs, visual field or acuity, and no adverse events.
Limits of this study
42 patients, single centre. All patients were also on timolol, so the result is for PEA as an add-on. The second crossover period was 1 month, shorter than the first. Registered UMIN000002833. Funding not stated in the abstract.
Source
PubMed 21705689 · doi:10.1167/iovs.10-7057
Entry checked against the abstract, supplied by Devlin on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.